Evidence map›Paper›PMID 41100188›Full record

ArticleEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery2025

Neoadjuvant Chemoimmunotherapy in Non-small-cell Lung Cancer Patients: Effects on Pulmonary Function and Incidence of Postoperative Pulmonary Complications-A Multicentre Real-World Study.

Jian Zhang, Yi Feng, Shaohua Dai, Guoqiu Xu, Bo Cheng, Lei Jiang, Li Peng Xue, Wenhua Liang, Jian Tang

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jian ZhangDepartment of Thoracic Surgery, Jiangxi Clinical Research Center for Respiratory Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Yi FengDepartment of Thoracic Oncology and Surgery, Guangzhou Institute of Respiratory Health, China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510120, China.
Shaohua DaiDepartment of Thoracic Surgery, Jiangxi Clinical Research Center for Respiratory Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Guoqiu XuDepartment of Thoracic Surgery, Jiangxi Clinical Research Center for Respiratory Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Bo ChengDepartment of Thoracic Oncology and Surgery, Guangzhou Institute of Respiratory Health, China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510120, China.
Lei JiangDepartment of Thoracic Surgery, Jiangxi Clinical Research Center for Respiratory Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
Li Peng XueDepartment of Thoracic Oncology and Surgery, Guangzhou Institute of Respiratory Health, China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510120, China.
Wenhua LiangDepartment of Thoracic Oncology and Surgery, Guangzhou Institute of Respiratory Health, China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510120, China.
Jian TangDepartment of Thoracic Surgery, Southern Hospital, Southern Medical University, Guangzhou 510515, China.ORCID 0009-0000-1438-9449

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the effects of neoadjuvant chemoimmunotherapy on pulmonary function and the incidence of postoperative pulmonary complications in real-world non-small-cell lung cancer patients.

methodsA retrospective analysis of stage II-IIIB non-small-cell lung cancer patients who received neoadjuvant chemoimmunotherapy across 3 medical institutions was conducted. Clinical data and perioperative outcomes were evaluated.

resultsA total of 386 patients were screened and enrolled in the study cohort, and all patients underwent surgery after completing neoadjuvant chemoimmunotherapy. Postoperatively, 61 patients developed postoperative pulmonary complications, among whom 25 were diagnosed with checkpoint inhibitor-related pneumonia. The postoperative mortality rate was 2.8% (11/386), with all deaths attributed to severe postoperative checkpoint inhibitor-related pneumonia. The diffusing capacity of the lung for carbon monoxide tended to decrease after neoadjuvant chemoimmunotherapy, with 39% of patients developing impaired pulmonary function post-treatment. After controlling for confounding variables via propensity score matching analysis, impaired pulmonary function after treatment was associated with postoperative pulmonary complications. Multivariable logistic regression analysis revealed that prior lung disease (odds ratio, [OR]: 1.63; 95% CI, 1.02-3.31, P = .037), impaired pulmonary function after treatment (OR: 2.78; 95% CI, 1.38-5.24, P < .001), lymph node metastasis (OR: 3.05; 95% CI, 1.65-6.21, P < .001), and elevated preoperative interleukin-6 levels (OR: 1.58; 95% CI, 1.36-1.83, P < .001) were high risk factors for postoperative pulmonary complications.

conclusionsImpaired pulmonary function after neoadjuvant chemoimmunotherapy is associated with the development of postoperative pulmonary complications. Post-treatment impaired pulmonary function, lymph node metastasis, prior lung disease, and elevated preoperative interleukin-6 levels are risk factors for postoperative pulmonary complications. CLINICAL REGISTRATION NUMBER: A Retrospective Study on Pulmonary Function Changes and Safety in Patients Receiving Neoadjuvant Chemoimmunotherapy (IIT2024733).

Indexed as

Carcinoma, Non-Small-Cell LungImmunotherapyLung NeoplasmsNeoadjuvant TherapyPostoperative ComplicationsAgedFemaleHumansIncidenceMaleMiddle AgedPneumonectomyRespiratory Function TestsRetrospective Studiesneoadjuvant chemoimmunotherapypostoperative pulmonary complicationspulmonary function tests

Identifiers

PMID41100188
PMCPMC12597875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.